chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a consumer and a school nurse concerning 41 child patients who in approximately 1995 were each vaccinated with a dose of varicella virus vaccine live. In approximately 2003, the patients developed mild cases of chickenpox.  Most of the children were in the first grade and had been vaccinated at their private pediatrician's offices in the area. The reporter noted that her elementary school was the only one out of six in the area that has experienced a chickenpox outbreak. The reporter notified the elementary school parents of the outbreak. Follow up information from the nurse indicated that 13 of the reported 41 patients were not previously vaccinated with a dose of varicella virus vaccine live and all of the cases of chickenpox have recovered. One of the previously vaccinated patients was a 7 year old patient who on 07JAN1996 was vaccinated with a dose of varicella virus vaccine live. On 13MAR2003, the patient developed chickenpox. The previously vaccinated patients included two siblings in elementary school who were vaccinated by the same pediatrician and subsequently developed mild outbreaks of chickenpox. The other patients that developed chickenpox post vaccination with varicella virus vaccine live were also identified.  Additional information is not expected.
This case was reported by a nurse and described the occurrence of an injection site reaction in a 5 year old male pt who received DTAP (Infanrix) for prophylaxis. The vaccine provider submitted this report directly to the local health department. On 04/17/03 the pt received the 5th dose of Infanrix in the left arm. On the same date, he received an injection of IPV in the left arm and an injection of MMRII in the right arm.  On 04/18/03, 24 hours post-immunization, the pt experienced an injection site reaction characterized by pain, swelling and inflammation. The pt's left arm was stiff. The pt also experienced irritability and low-grade fever. The events resolved on 04/20/03.  The nurse considered the events were related to vaccination with Infanrix.
Kinrix given instead of pediarix. No treatment needed at this time. No adverse reactions noted at this time. Mother to watch for adverse reactions.
COVID vaccine breakthrough case. Pfizer 1/20/21 EL3249, 2/10/21 EM9810, and boosted 11/1/21 EW0164 and 5/16/22 FM7553.
Non-stop fevers; A spontaneous report was received from a consumer who was also a 72-years-old male patient who received Moderna's COVID-19 vaccine and experienced  non-stop fevers of 98 and above, but not 100.  Patient's medical history was not provided, and no report on concomitant medicines.   On 8/Feb/2021 2020, approximately 2 day prior to the onset of the symptoms, the patient received their first of two planned doses of mRNA-1273 intramuscularly in the right arm for prophylaxis of COVID-19 infection.  On 9/Feb/2021, the patient felt non-stop fevers of 98 and above. symptoms were resolving.   No Treatment was taken by the patient  Action taken with mRNA-1273 was not reported.  The outcome of the events, non-stop fevers of 98 and above  was considered to resolving.
The morning after the vaccination, I awaked to chills, later I experienced fatigue and fever, shortness of breath with exertion for 2 1/2 days, loss of appetite and nausea for 5 days, all resulting 1 missed day from work. and I am still after nausea after eating  at the time of this report.
Got flu shot 1NOV91 & began sx of diarrhea, fatigue, anorexia, & nausea on 5NOV91; progressed to weakness & jaundice by 10NOV91 Seen by MD got ATB starting falling down alot on 13NOV91; admitted to hosp 20NOV91 dx w/encephalomyelitis;
Ice pick headache behind eye on same side as shot (left) - persistent for 3 days Chills / sweats - persistent for 2 days Slight fever - persistent for 2 days teeth ache on left side (same side as shot) -  persistent for 2 days
This spontaneous report as received from a pharmacist refers to an unspecified number of patients of unknown age and gender. The reporter reported that an unspecified number of patients were administered doses of ZOSTAVAX (lot#, dose, dose# and route unspecified) which were improperly stored since an unspecified date in June 2014. No adverse events were reported. The outcome of the event was not reported. Additional information has been requested.
Case number PHEH2014US024366, is an initial spontaneous report received from a nurse on 02 DEC 2014, with a follow up received from  nurse on 21 JAN 2015. This report refers to an 80 years old male patient. His medical history was not reported. Concomitant medications were none. The patient had tolerated the vaccines well in the past. He was vaccinated with FLUVIRIN 2014/2015 (batch number: 14511P, expiry date: MAR 2015) intramuscularly into the left deltoid at a dose of 0.5 ml on 03 NOV 2014. Nurse reported that PFS of FLUVIRIN was stored at 49 degree F for 1 hour and 15 minutes. The patient did not experience any adverse reaction due to the maladministration (incorrect storage of drug). Follow up received from nurse on 21 JAN 2015: Updated site of vaccination and reporter comment.
Initial report received from a nurse on 25 August 2011. A 66-year-old male patient had received a subcutaneous left deltoid injection of YF VAX on 17 August 2011 (lot number UH109AA) and 4 days later on 21 August 2011 developed a macular rash on his trunk and back that radiated to the left side. He also complained of chills and body aches. The patient did not require medical evaluation and so no relevant diagnostic tests and/or laboratory data were performed. The patient had no concurrent illnesses, and had not experienced any adverse events with prior vaccinations in the past. He had not received any other vaccinations within 4 weeks prior to 17 August 2011. The reporter did not know if the patient had any pre-existing medical conditions or was using any other medications at time of vaccination. At the time of this report the patient had not recovered. Follow-up information was received 14 October 2011 from a health care professional. The patient had not received any prior doses of YF VAX. The patient had previously received on 03 August 2011, a first dose left deltoid intramuscular injection of TYPHIM VI (lot number E1287) and a first dose intramuscular right deltoid injection of Hepatitis A vaccine (other manufacturer, lot number AHAVB520AA). The patient had a history of high blood pressure and developing a rash with amoxicillin. The patient denied any history of cancer, leukemia, AIDS, seizure, brain or nervous system problems. He had not received any blood transfusions or gamma globulin during the past year. Concomitant medications consisted of Propanolol 10mg BID, DIOVAN 160 1/day, Triamterene HCTH 75/5 1 daily, Diazepam 5mg prn, Simvastatin 80 and Nifedical 30. At the time of vaccination, the patient had no concurrent illness. According to the reporter, the events did not require treatment and the patient recovered (date not reported). Documents held by sender: None.
27NOV91 12noon had emesis @ school, did not feel well; c/o h/a & some fatigue; sent home; pt had sz lasting approx 1 min; pt has poor appetite, tonic movement of lt ext, eye rolled back, unresponsive, sleepy, hypotension, dehydration;
Patient received second dose of Moderna approx 0900. At 9:17 patient's caregiver informed Nurse mother was feeling SOB. Pt assissted to monitoring area and placed per request.  AAOx3, difficulty articulating speech r/t CVA, PEG-tube in place. BP 146/71, 63, RR 20. S1S2 present, Lungs clear to auscultation and BS +4 all quads. Hx of Stroke, MI, Emphysema ( O2L @ home HS) and Dysphagia. Pt informed nurse SOA was subsiding, no medications administered. VS prior to D/c home 1134/62, 56, RR18.
Caller states that product was administered to patient following the temperature excursion; No additional AE; This spontaneous report was received from a medical assistant and referred to a patient of unknown age and gender. The patient's concurrent conditions, medical history and concomitant therapies were not provided.  On an unknown date, the suspect vaccine was improperly stored at temperature of 34.4 degrees Fahrenheit for a time frame of 15 hours (product storage error). On 27-APR-2023, the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, 0.5 ml, once, lot #W004648, expiration date: 06-OCT-2024, administered for prophylaxis (strength, and route of administration were not provided) following the temperature excursion. No symptomatic adverse events were reported.
After severe nosebleed unexpected and unusual twenty four hours after shot; Immunization; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A female patient received bnt162b2 (BNT162B2), administration date 29Sep2021 (Batch/Lot number: unknown) at the age of 70 years as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1), for COVID-19 Immunization; Bnt162b2 (DOSE 2), for COVID-19 Immunization. The following information was reported: IMMUNISATION (non-serious) with onset 29Sep2021, outcome "unknown", described as "Immunization"; EPISTAXIS (non-serious) with onset 30Sep2021, outcome "unknown", described as "After severe nosebleed unexpected and unusual twenty four hours after shot". No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Sore muscles in shoulder & arm.  Dull general soreness not localized.  Painful during some movements of arm.
Fever and muscle aches,  Sleeplessness related to previously stated; 800 mg ibuprofen, approximately 6 hours post beginning, symptoms appear to have passed after 12 hours.
While I intended to order PEDIARIX and Hib, I incorrectly wrote PEDIARIX, Hep B on the order to the MA, who administered them 10/23. Thus the pt received two Hep B. I called his mother who said she saw no reaction or fever. She has sched. him to come in to get the Hib Iz.
A week after the shot my blood pressure spiked and has not gone down yet. It was well controlled before the shot. I have been to the emergency room twice and to the cardiologist. No meds are working.
This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Sore arm at the vaccination site), FATIGUE (Tiredness), CHILLS (chills), ARTHRALGIA (Severe shoulder pain/ joint pain in both shoulders) and INSOMNIA (It makes it hard for him to sleep) in a 50-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 018B21A) for COVID-19 vaccination. No Medical History information was reported. On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Mar-2021, the patient experienced VACCINATION SITE PAIN (Sore arm at the vaccination site) and FATIGUE (Tiredness). On 22-Apr-2021, the patient experienced CHILLS (chills). On an unknown date, the patient experienced ARTHRALGIA (Severe shoulder pain/ joint pain in both shoulders) and INSOMNIA (It makes it hard for him to sleep). On 28-Mar-2021, VACCINATION SITE PAIN (Sore arm at the vaccination site) and FATIGUE (Tiredness) had resolved. On 25-Apr-2021, CHILLS (chills) had resolved. At the time of the report, ARTHRALGIA (Severe shoulder pain/ joint pain in both shoulders) and INSOMNIA (It makes it hard for him to sleep) outcome was unknown. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. This case was linked to MOD-2021-207772.
16:06 Lightheaded + sore throat, HR 86, SO2 RA: 99% BP 168/110 16:30 Pt left asymptomatic.  She stated she was having high blood pressure earlier that day, so it may not be a side effect of the injection.
Friday 2/5/21 Midday I became very tired 5:00 exhausted.   7:00 got into bed and fell asleep My shoulders, back, and joints were aching 10:30 p.m. woke up and had yogurt & frozen fruit, drank about 8 oz of juice, went right back to sleep Dizzy and lightheaded on and off - noticed when I got up to use the bathroom and Sunday most of the day. Slept until Sun 2/7/21  Woke up at 7:00 got washed, laid down, went back to sleep until 11:00 a.m. Showered. Still tired, fought to stay awake.  Joints still hurt, dizziness, and lightheadedness By Monday, late afternoon, the early evening started to feel better.
On 10/1/20 patient received PCV13. On 12/20/21 patient received the same vaccine. Series administered incorrectly.
Headache, Arthralgia, Fever, NauseaVomiting, chest pain, right arm soreness, lethargic Narrative:
Infant developed fever to 102.9 within 12 hours following vaccine administration. Had 2 episodes of vomiting.
Two days ago ( 6/13/22)pt. received his MMRV and DTap-IPV vaccines. Both were given in the left thigh. about 12 hour after administration of the vaccines mother noted 4-5cm area of redness around on his left thigh. The following morning (about 24 hours after the vaccines were given) the area of redness was much larger. Her photo shows an area of about 10x13 cm of redness. Today (48 hours after administration) the area of redness is even bigger. Discomfort is not worse. Mother gave him zyrtec but not sure if it did anything for him. He has complained of itching and irritation , he has no fever, not limping.
No adverse event; The vaccination card states that the patient received a Bivalent booster dose for the first primary Moderna COVID-19 vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG PRODUCT ADMINISTERED (The vaccination card states that the patient received a Bivalent booster dose for the first primary Moderna COVID-19 vaccine) and NO ADVERSE EVENT (No adverse event) in a 54-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     It was unknown whether patient did not receive any other vaccines in the 4 weeks prior to COVID-19 vaccine.     On 31-Jan-2023, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 31-Jan-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced WRONG PRODUCT ADMINISTERED (The vaccination card states that the patient received a Bivalent booster dose for the first primary Moderna COVID-19 vaccine). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (The vaccination card states that the patient received a Bivalent booster dose for the first primary Moderna COVID-19 vaccine) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (The vaccination card states that the patient received a Bivalent booster dose for the first primary Moderna COVID-19 vaccine).    No concomitant medications were provided. No treatment medication was provided.   Reporter did not allow further contact
Pt experienced flu like symptoms 24 hours post vax. Pt had fatigue, muscle ache, nausea and fever.  Pt also experienced pain at injection site, swelling, redness and itching.
patient made patient sick two years ago; Initial information regarding an unsolicited valid non-serious case received from a consumer (Patient) social media and transmitted to Sanofi on 23-Oct-2020.  This case involves patient with unknown age who INFLUENZA VACCINE (produced by unknown manufacturer) (lot number unknown) via unknown route in unknown administration site for prophylactic vaccination made patient sick two years ago (Illness).  Medical history, medical treatments, vaccinations, concomitant medications and family history were not provided.   Final diagnosis was Illness.  No relevant laboratory tests were reported.   It was not reported if the patient received a corrective treatment.  Event outcome was reported as Unknown for Illness.  There will be no information regarding batch number for the case.
Initial report received on 27 August 2012 from an investigator. A 22-year-old male subject who had no past medical or surgical history, and who had not been taking any concomitant medications, had received ACAM2000 (route, site and date of administration not reported). On 16 February 2011, an unspecified amount of time after receiving the vaccine, he had normal Rapid Troponin I levels and elevated central laboratory Troponin I levels (2.60 ng/mL). ECG performed on 22 February 2011 had normal interpretation with findings of sinus tachycardia. Repeat tests performed on 22 February 2011 were normal. Outcome was recovered on 22 February 2011. The subject had never taken topical steroids to treat an eye problem or disease, and he was not allergic to any medications. Alcohol consumption was reported as 2-3 times per week (average three drinks per day). Consumption of five drinks or more on one occasion was reported 2-4 times a month, with consumption of 9 drinks reported in a typical week. The subject had a past history of smoking beginning at age 15. He smoked on average less than half a pack per day for one year. The subject quit smoking successfully. According to the investigator, this event was possibly related to vaccination with ACAM2000, and was considered an Other Important Medical Event. This represents a case of potential myopericarditis per the Investigator and has subsequently been referred to the ACAM2000 Myopericarditis Adjudication Committee for assessment. Documents held by sender: medical records.
EXTREME and disabling full-body joint and muscle pain for three (3) days and fever of 101 degrees F for the first two (2) days? all starting the morning after receiving the second vaccine.
itchy rash that started on my stomach, then to thighs, then to back.  Site of shot was also very itchy.  Rash began receding on Sunday, March 7, 2021 --itching pretty much stopped, except for site of shot.  Rash pretty much gone by Monday, March 8.
received only the liquid portion of menveo; received only the liquid portion of menveo; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis.   On an unknown date, the patient received Menveo. On an unknown date, unknown after receiving Menveo, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.   Additional Information: GSK Receipt Date: 19-Jul-2022 Reporter's comment: Healthcare professional reported the patient received only the liquid portion of Menveo. The consent to follow up was given. No other details available. Additional Supportive Information: The patient received only the liquid portion of Menveo, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered.
Pt recv vax on 1/25/99; on same day pt exp swelling at vax site, rash on body; tx=IV steroid therapy
Breakthrough case admission after 4 vaccines Pfizer 3/31/21 lot# Ew0150;  Pfizer 4/2/21 lot# ER8735;  MOderna 12/22/21 lot# 070H21a;  Moderna 12/1/22 lot# 059F22A
Severe kidney pain that night, so bad it woke me up and I couldn't sleep from it. It felt like I had been punched in my lower back for days. It's the worst kidney pain I ever felt.
This spontaneous report was received from a 55 year old female patient reporting on herself. No medical history or concurrent conditions were reported. On 10-OCT-2014, the patient was vaccinated with ZOSTAVAX, 0.65 ml, subcutaneous in the arm (lot # reported as 1225925-03015). Concomitant therapies were reported as unspecified medications. On 10-OCT-2014, the patient reported that her arm was red and started swelling up after she was administered with ZOSTAVAX. The patient also stated that she had a bump at the injection site. On 14-OCT-2014, the swelling started to go down some, but now (approximately in October 2014), the injection site was itching. The patient stated that the ZOSTAVAX was applied on a pharmacy. Treatment was suggested (ice on the injection site), no labs diagnostic studies were performed and the patient sought medical attention (went back to pharmacy where shot was given). At the time of the report, the outcome of redness, itching and the bump at the vaccination site was not recovered. The outcome of swelling at the vaccination site was recovering. The causal relationship between the events and ZOSTAVAX was unknown. Lot number 1225925-03015 is an invalid lot number for ZOSTAVAX. Additional information has been requested.
This spontaneous report has been received from an officer manager referring to a patient of unknown age and gender. No information was provided regarding the patient's medical history, concurrent conditions, drug, allergy history or concomitant medications. On 18-MAY-2018, the patient was vaccinated with a dose of improperly store Oka/Merck VARIVAX lot # N008829, expiration date 16-MAR-2019 for prophylaxis (strength, frequency and route of administration were not provided). Concomitant therapies included MRK STERILE DILUENT. The doses of varicella Oka/Merck VARIVAX were exposed to a temperature excursion of 6°Fahrenheit (°F) to 14°F during a time frame of 12 minutes and 15°F to 46°F for 3 hours and 30 minutes, which was detected by the data logger. There was no previous temperature excursion. No adverse effects were reported.
Pt has had increased difficulty breathing for 3 days and is on home oxygen. She has COPD and has been giving herself 4 nebulizer treatments per day without improvement. She has had upper respiratory symptoms. She is found to have COVID-19 and pneumonia.
Seconds after administering the vaccine, the inj. site right arm got swollen and turned bluish green. Patient got a little dizziness that was gone in less than one minute. BP and breathing an all other vitals was normal. Patient recovered totally with only soreness by end of day.
Case received from a healthcare professional in the USA on 22/Nov/2005 via the MIS/VIS under the reference number 05-0700. This case is included in a cluster of 5 cases and is linked with 2005-02542,2005-02543,2005-02545 and 2005-02546 cases. A 1 year old female patient with no medical history noted had received on 05/Nov/2005 his first intramuscular dose of influenza vaccine (Fluzone), batch number U1819AA and 2 days later, i.e. on 07/Nov/2005 she experienced temperature at 100-100 degrees F, "slight red" and mild cold symptoms. It is worthy noting that the patient received her third intramuscular injection of Hepatitis B vaccine (other MFR), batch number 0336R in the left leg and her first subcutaneous injection of Varivax (other MFG), batch number 0427R in the left thigh on 26/)ct/2005. The patient did not present with any illness at time of vaccination. The patient was recovered on unspecified date. Follow up information received on 15/Feb/2006 from a health care professional. Per the reporter the patient had the injection in the left thigh. No relevant diagnostic tests/laboratory data were collected.
Pt recv vax on 11/3/98; on 11/5/98 pt exp rash on arms & thigh, swollen throat; dx=virus; 11/16/98 pt exp rash on feet w/ itching, seen in E.R.; dx=allergic rx